Free Due Diligence

WUHN .52…
See the source image
*New Videos posted 08/16/2020

M2Bio Sciences & Juvenescence – 7. The Potential of the Medical Psychedelics

M2Bio Sciences & Juvenescence – Full Interview with Dr. Greg Bailey

Gregory Bailey, M.D., is CEO of Juvenescence Limited, a company that develops therapeutics, so people can have healthier, longer lives.    Dr Bailey has been founding and financing life science companies since 1995. Some of these companies have traded on NASDAQ, AIM, AMEX and NYSE, reaching over $18 billion in market capitalization. He co-founded Ascent Health Care in 1995, which was sold to Stryker for $525 million in 2009. In 2004, he was the initial financier and a board member of Medivation, Inc. (MDVN: NASDAQ). It was ultimately acquired by Pfizer in September 2016 for $14.3 billion. In January 2014, Dr Bailey along with his partners capitalized Biohaven through Portage Biotech with $3.5 million, subsequently adding a further $3.5 million over the next two years. Biohaven went public May 2017 on NYSE. Portage was the major shareholder in Biohaven until it did a dividend of $210 million of Biohaven shares to Portage shareholders. Dr Bailey remains a major shareholder of Biohaven, which has a market cap of a little over $1.5 billion.

Greg Bailey and British entrepreneur Jim Mellon have invested in Beckley Psytech, a new company developing a pipeline of psychedelic drugs into licensed pharmaceutical medicines for treating psychiatric and neurological diseases.

https://www.psychedelicfinance.com/articles/global-investors-back-psychedelic-medicine-start-up-with-3-8m-series-a-round?utm_campaign=Internet%20Bull%20Report%20-%20Discovering%20Remarkable%20Opportunities&utm_medium=email&utm_source=Revue%20newsletter

A further look at Jim Mellon… https://en.wikipedia.org/wiki/Jim_Mellon  Jim Mellon

Born   James Mellon

February 1957 (age 63)

Edinburgh, Scotland

Nationality   British

Education     University of Oxford

Occupation  Businessman

Net worth    Increase £1.1 billion (May 2019)[1]

Mellon founded the uranium mining company Uramin in 2005 with just $100,000. Also listed on the stock market in 2006, it sold the following year to Areva for around £1.6 billion, reportedly making him about £80 million. Areva later had to accept a huge write-down in Uramin’s value.[4][

Outstanding Shares
43,271,310
02/10/2020
Regarding this share structure , Item 7 page 6. This block of 19,844,398, the is in the process of being retired by the company and cannot be traded at this time. This would put our total outstanding at under 25 million. The company stated it  is currently working on their corporate filings to become current on OTC markets which will remove the STOP sign. https://www.otcmarkets.com/stock/WUHN/disclosure
From the recent filing showing the 19,844,398 Block mentioned above
Fame Good International Limited (Xu Jie) Shareholders Quan Hubei, China 19,844,398 common 45.86%
I am using that 25 million  number for general comparison below.The total market cap for WUHN based on these numbers would be under 10 million dollars. If WUHN were trading at $1.00, it would have a market cap of 25 million. This is still far below other companies in the sector . It is my opinion, is M2Bio  still undiscovered. Here are a few examples of companies in the sector and their respective market caps.Another important element to remember is, WUHN has been self financed to this point. I pay special attention when management steps up with their own money to move operations forward. Most of these other companies have already been selling stock to raise capital.
WUHN    $ 10,000.000 
SHRMF   $ 49,276,401
NLBIF      $ 76,531,919
MMEDF   $ 84,281,464
LKYSF     $ 28,990,668
RVVTF    $ 43,564,019
WUHN is listed on this new  Psychedelics Index …
The  company web site, Follow the entire story as it’s unfolding…
Wuhan General Group is a Nevada state public incorporation trading on the Over The Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
The Company is currently positioning itself to become a major player in the 146.4 billion dollars growing medical CBD (cannabidiol) space as well as the promising psilocybin medical health sector. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies. has entered CBD by-product market.
Wuhan General Group through its wholly-owned subsidiary MJ MedTech, a nutraceutical company that researches, develops and commercializes a range of CBD-based products is launching of its premium CBD product lines which includes the CBD cosmetics line and the CBD coffee line in pharmacies, convenience stores and hotels across South Africa. The products are branded under the trademarks: DrAnnaRx™ and Medspresso™ respectively.
In addition, its new division, M2BIO aims to explore and develop additional indications for psilocybin new therapies that will help patients who suffer from mental illness. Wuhan has been researching multiple medicinal mushroom types in order to formulate its upcoming range of cosmetics, coffee, and teas for commercialization in early Q1 of 2020 within its M2Bio division.
The Company, with its multiple partnerships with Cape Town-based manufacturer and merchandiser of premium health products to all pharmacy & health shop chains across South Africa, will be launch Dr. AnnaRx and Medspresso products and distribute in 1000 stores and pharmacies in South Africa and adjacent countries. Our next phase is to go international: US, Canada, and Europe.
M2BIO is a division of MJ Medtech that aims to help take psilocybin-based medicine to the forefront by deploying solid medicine,  commercial products, and clinical research. Work is being done to further understand the implications of psilocybin use in a number of disease states. Certain mental health disease states and symptoms have been studied, including depressed mood, anxiety disorders, obsessive-compulsive disorder, alcohol abuse, and tobacco abuse. M2BIO is currently doing an in-depth review of studies performed and their results for each of these conditions and evaluating the clinical potential for use.
Our Team..
Jeff Robinson  CEO M2Bio
The ceo has a strong following on twitter and is also on facebook. He is also  the CEO of the Internet Bull Report linked below.
Dr. Anna Leralta Chief Medical Officer M2Bio..
  • Doctor of Medicine and Surgery Lausanne, Canton of Vaud, Switzerland
Dr. AnnaRx™ is wholly-owned international trademark of MJ Medtech used for the branding of its line of by-products and medical research with our high-end Broad-Spectrum Cannabidiol (CBD) is of the highest purity and potency and includes other beneficial cannabinoids, terpenes and molecules, that help promote healthy body and skin care,  under the umbrella of Dr. Anna Leralta recommendations.
In South Africa, MJ MedTech will be offering through Dr. AnnaRx™ brand CBD by-products in over 1000 stores and pharmacies, aiming to reach 4000 locationss by end of 2020. Over 40 product lines encompassing supplements, ointments, foods, and many other products will be sold in stores and online on our e-commerce drannarx.com where it is legally permitted.
I have been searching for a psilocybin (mushroom) medical stock. I came across several and right now I like this one best as a buy/hold type play. There is a new podcast that was released this morning and posted below. I think this sector is still very under the radar and untapped. There aren’t that many public trading stocks in this sector. This company has several divisions including Pharma grade CBD. After doing a quick research on the CEO, I believe he has strong credentials in the sector and the overall area of medical science. The company is in the process of getting current in their filings for transparency. There was also a recent name change and rebranding to M2Bio Sciences.
05/22/2020 
*A New CEO,  Well rounded Interview that sums up their business that I believe is important to listen to. Jeff has a well blended background which incorporates the business side along with the many elements in running a Public company.This is a very rare combination to find in the public markets.Follow the story.

Terry Booth Departs Aurora Board, Shifts Focus to Psychedelics

 Psychedelic Medicine Stocks Capture The Attention Of Investors

  Miami researchers discover process to sustainably produce psilocybin – a drug candidate that could help treat depression
  Johns Hopkins Scientists Launch Center For Psychedelic Research. Say Psychedelics Could Treat Alzheimer’s, Depression and Addiction
Push to legalize psychedelic mushrooms in Oregon picks up steam

Labat Africa reports investor interest as South Africa publishes medical cannabis notice

https://www.engineeringnews.co.za/article/labat-africa-reports-investor-interest-as-south-africa-publishes-medical-cannabis-notice-2020-06-29/rep_id:4136 

  Let’s look at the recent News and progress. follow the story. M2Bio has been building a team of quality talent with each appointment having a strong presence in their respective areas of expertise….
06/03/2020

Wuhan General Group Strengthens Team with New Appointments

https://www.otcmarkets.com/stock/WUHN/news/story?e&id=1617362 

Mr. Johann McLoughlin hails from the creative hub of Cape Town, South Africa. He joins Wuhan effective immediately as Director of Product Development and Visual Communications and Design.
Mr. Selah Abrams resides in Los Angeles and has joined Wuhan as Director of Corporate Strategic Partnerships. Mr. Abrams worked for CNN as a Broadcast Production Engineer for 12 years, and prior to that as Director of Media and Technology for CV Sciences, Inc. an early player in the cannabis sector.
Mr. Luka Marjanovic will be assuming his new role as Director of Human Resources and Communications effective immediately.
Mr. Rameez Adair of Johannesburg, South Africa has joined the team as Director of Social Media. In his role, Mr. Adair will be responsible for planning, implementing, managing and monitoring Wuhan’s social media strategy in order to increase the Dr. AnnaRxTM and MedspressoTM brand awareness, improve marketing efforts and increase sales.
Wuhan CEO Jeff Robinson stated: ‘‘We are on the verge of some very considerable growth and managing it will be critical. Bringing aboard great talent is key for us at this juncture as it provides us all with a greater depth of expertise from which to draw upon and the tools we need to execute and succeed. I’m beyond ecstatic to see our Wuhan planned journey unfold for our shareholders.”
 06/10/2020

Wuhan General Group Signs Distribution Agreement with Medigrow for International Distribution Rights of Medical Cannabis Products

https://www.otcmarkets.com/stock/WUHN/news/story?e&id=1621828 

“We see many strategic business opportunities to expand our relationship with Medigrow and this Agreement is the first of many other significant associations going forward with our partner. The Medigrow portfolio of international-grade medical cannabis products is a very tactical addition to our range of products and it really strengthens our commitment to medical cannabis,” said Jeff Robinson, CEO of Wuhan.
A look at Medigrowafrica  Operations…
The Founder – Willem Daniel Jonker
The founder of Medigrow Africa is a chartered Accountant (South Africa) by training. He was a senior partner at Allan Gray (www.allangray.co.za), the largest independent investment manager in South Africa, until 1993. Thereafter he moved into the field of private equity, arranging funding for companies such as Medigrow Africa. linkedin.com/in/willem-jonker-9271a91
Willem Jonker is the Godfather of MJ in Africa, the magnitude of what’s transpiring with M2Bio, has not yet been discovered by the masses. Follow the story.
Interview #1…  
CEO interview with Willem Jonker, CEO and Founder of MediGrow Africa
Interview # 2… 

Wuhan; What Jeff and Willem look for in a Company

https://www.youtube.com/watch?v=jYNFgIgi4gM

Interview # 3…
Working from Different Angles with the Same Mission
Interview # 4…
Companies that Raise Capital VS those that Define an Industry
Interview # 5 …
The Benefits of Partnering with MediGrow Africa
More with Medigrow AFrica…
The Kingdom of Lesotho 
Medigrow Lesotho…
Cost effective to Grow in South Africa
06/18/20

Wuhan General Group Announces Name Change and Rebranding to M2Bio Sciences

https://www.otcmarkets.com/stock/WUHN/news/story?e&id=1627479

“The new name M2Bio has been chosen to better reflect the company’s strategic focus on applying Marijuana and Mushrooms into the roots of its research and development of plant-based medicine and drug discovery, and to mark a new chapter in the Company’s growth. We are so deeply committed to developing innovative, better and safer medicines that will truly help treat patients,” said Jeff Robinson, CEO of M2Bio.
M2Bio mentioned here…

Wuhan; Alcoholism and other Targets to go after

https://www.youtube.com/watch?v=KK61pB3spj8

06/24/2020

Wuhan General Group Signs Manufacturing, Distribution and Sales Agreement with Cafféluxe     

  https://www.otcmarkets.com/stock/WUHN/news/story?e&id=1631128

The Cafféluxe agreement will enable Wuhan to enter legal, international markets around the globe, and to develop a centralized distribution channel for its suite of functional foods and wellness products.
 More with Caffeluxe who is in more than 30 Countries and our Medspresso product already in launch…
We are delighted to share with you first, a new brand about to launch: Medspresso™.
Recent Interviews with the CEO of Caffeluxe..
M2BioSciences; Picking a Target Market with Caffeluxe
https://www.youtube.com/watch?v=Wb1pGhAgb1I&list=PLKZqbE_bHrKFlxXHSBqZoaLn7TJrP8R1l&index=5M2Bio Sciences; The Power of Capsules for the Everyday Coffee Drinker
https://www.youtube.com/watch?v=HORw5oWxCfk&list=PLKZqbE_bHrKFlxXHSBqZoaLn7TJrP8R1l&index=6
07/01/2020

Wuhan General Group Signs Collaborative Partnership LOI With Jugular for CBD Functional Foods

https://www.otcmarkets.com/stock/WUHN/news/story?e&id=1636165

The New Interview…  https://www.youtube.com/watch?v=UFNQRVsuufs&feature=youtu.be 

Immune Booster Shot: The pandemic has caused a significantly heightened awareness for immune-boosting supplements that are easily ingested. Special African medicinal roots and herbs are used in combination to create this very powerful immune booster tonic.
Energy Booster Shot: Quick energy on the go. The ultimate coffee powered CBD infused shot to get added energy into your system and amplify mental clarity quickly and effectively.
Relax and Unwind Shot: This powerful formulation of Rooibos, CBD, and 8 other African medicinal herbs will help relieve many of the tensions built up during the day enabling you to enjoy a most peaceful sleep.
Jack and I have spent immeasurable hours over the past few years discussing food science and how we might see a fit in bringing the brains behind our organizations together. We are thrilled to make this a reality and to be working with a group that cares as much about the science as we do” said Jeff Robinson, Chief Executive Officer of Wuhan General Group.
About Jugular
Jugular is an innovation partner within the wellness sector, implementing our skills to bring new functional food & nutraceutical products from concept to market. Jugular comprises a cross-specialized team of wellness professionals and scientists that are passionate about making a positive impact on the world by advocating a healthy lifestyle through innovative products that are good for you. We own multiple functional food brands that are sold throughout Europe and distributed Internationally.
07/17/2021

Wuhan General Group Signs MOA for the Acquisition of Tsime Pharmaceuticals (PTY) Limited

08/21/2020

Wuhan General Group Corporate Update

Let’s now look at the Mushroom side of the business. We haven’t yet heard from the company in depth regarding this Division. The videos I found and review of the web site, indicate we wont be waiting much longer.
MJ MedTech is a Canadian-based wholly-owned subsidiary of Wuhan General Group, a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx and Medspresso brands. In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies to help alleviate everyday illness.
M2BIO is a division of MJ Medtech that aims to help take psilocybin-based medicine to the forefront by deploying solid medicine,  commercial products, and clinical research. Work is being done to further understand the implications of psilocybin use in a number of disease states. Certain mental health disease states and symptoms have been studied, including depressed mood, anxiety disorders, obsessive-compulsive disorder, alcohol abuse, and tobacco abuse. M2BIO is currently doing an in-depth review of studies performed and their results for each of these conditions and evaluating the clinical potential for use.

Wuhan; How Far can the Industry Go?

https://www.youtube.com/watch?v=XV2b92cx834

The World’s Largest Psychedelic Research Center (#385)

What stage is M2Bio in  with their Science and Psilocybin?
Q1  2020 Conducted in vivo and in vitro testing
Q2  2020 Pre-enrollment Patient-screening
Q3  2020 Provisional patent for method and delivery of psilocybin to treat Alcoholism
Q4  2020 Start Phase 1 Human Trial
The Path…
*Drug Target discovery
*Preclinical Research ( In vivo/In vitro testing ) Concluded
*Phase 1    ( safety/Dosage )
*Phase 11  ( efficacy/side effects )
*Phase 111  ( effect/adverse events )
*FDA Approval  ( post-market survelliance )
My personal thoughts and opinions…
Jeff and his team seem to be very measured and methodical with rolling out the different divisions to their business plan. They have delivered substance where many of these companies deliver fluff and become share selling machines that regularly dilute shareholders for their own gain. I have had several conversations with  Jeff several times now via video connection from South Africa. His science background is vast . I found connections to Bio/Pharma companies that are listed on the NYSE. One of them is very large.
The company is aligning themselves with what looks to be the best in class with regard to each area of their revenue streams. We see that with  DR. Anna ,Willem Jonker, Caffeeluxe, and their new personnel appointments.
He is committed to high grade , exceptional products, Their CBD being Pharma grade. This coupled with their Mushroom science, will separate M2Bio from the pack. As you heard in one of the videos, production costs in South Africa are a fraction of what the cost here is in the USA. This is a substantial advantage.
<br>
 ~GRYN .75   (member alerted .12 ) with a high of  2.50  

 

Green Hygienics ticker (GRYN)

Authorized Shares: 375,000,000 – 2019-08-02
Outstanding Shares: 34,707,835 –  2019-08-02
Float:                             4,695,515 –    2019-08-02

Green Hygienics Holdings Inc. (GRYN)

About Us

“Hygienics” is the science of preserving and promoting the health of individuals, communities and the planet. The hemp plant is aligned with that and has a history use dating back thousands of years across many cultures. We are excited to be an advocate in an age where the deteriorating state of our soils, water systems and food supply are contributing factors in destroying our collective health. It is critical that we look to change this.  Our objective is to be part of creating a solution and profit by it as a result of doing it well.  Green Hygienics is establishing itself as a leader in the advancement of science-driven hemp cultivation systems with the objective in mind of providing the market with the best possible product and experience.  Our collective experience within the agricultural field in science and innovation is extensive.  The company will grow by; generating revenues from the sale of premium grade hemp and hemp derived products, developing and licensing valuable intellectual property assets, and both making strategic acquisitions of and developing valuable global consumer brands.

The company has integrated and is developing its own IP assets related to proprietary systems and apparatus, software, algorithms and custom-engineered hardware. This provides ultimate efficiencies in a commercially controlled cultivation environment. Utilizing the advantages of hybrid-aeroponics, Green Hygienics creates a sterile growing environment that produces consistent, high-quality product while maintaining the lowest possible carbon footprint. The company utilizes state-of-the-art, quality-controlled commercial cultivation methodology to assure production of pharmaceutical-grade cannabis at much higher yields and greatly reduced costs.

“The future of the Medical Marijuana industry in the US and Canada is happening right now, and GRYN is poised to disrupt”

Hygienics is the science of preserving and promoting the health of individuals, communities and the planet. In an age where pharmaceuticals and the food supply are contributing factors in destroying our collective health, it is critical that we look to change this. Our objective is to be part of creating a solution and profit by it as a result of doing it well. Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems with the objective in mind of providing the medical and recreational consumers with the best possible product and experience. The company will grow by; generating revenues from the cultivation and sales of premium grade cannabis derived products, developing and licensing valuable intellectual property assets, making strategic acquisitions, and creating trusted global consumer brands.

Quick overview:

*CEO Ron Loudoun Interview building a previous start up..  http://www.biz1on1.tv/segment/ron-loudoun-archer-cleantech-uncut-interview/
*18 filings since December and now current on OTC markets  https://www.otcmarkets.com/stock/GRYN/disclosure ;
*New web site still under development with updates.http://www.greenhygienicsholdings.com/
*low trading float around 4.7 million, filing showing insiders holding over 90% of the shares
*low outstanding shares updated this month… 34,707.835
*From the web site, now an OTCQB Listing fully transparent company.
<br>
Recent News…
08/26/2019
Green Hygienics Holdings Inc. Completes Acquisition of 824-Acre Potrero Ranch Hemp Cultivation Property

Keep it simple, the numbers are there for a huge stock price . This company in the below article  boasts as the worlds largest Organic grow, look at GRYN  numbers  in the above press compared to theirs. If GRYN is an Organic operation, they will be the Worlds largest with over 800 acres and command a much higher price per pound that the normal Hemp product..

https://www.newswire.ca/news-releases/world-s-largest-indoor-organic-hemp-cbd-grower-setting-up-in-manitoba-831163983.html

07/22/2019
Green Hygienics Holdings Inc. Secures License for Processing Hemp in the State of North Carolina
Green Hygienics Holdings Inc. Appoints New Management and Advisory Board to Lead Key Business Strategies
Green Hygienics Holdings Inc. Registered to Cultivate Industrial Hemp in San Diego County, California
Green Hygienics Holdings Inc. Secures Purchase Order for the Sale of Hemp to U.S. Tobacco De México
 Green Hygienics Holdings Inc. Secures Licenses for Cultivation and Processing of Hemp in the State of Michigan
https://www.otcmarkets.com/stock/GRYN/news/Green-Hygienics-Holdings-Inc-Secures-Licenses-for-Cultivation-and-Processing-of-Hemp-in-the-State-of-Michigan?id=225947
*Green Hygienics Holdings Inc. to Purchase 824-Acre Potrero Ranch Property Near San Diego
Matt Dole, Vice President of Business Development, stated, “Given that there is the potential to harvest 1,200 to 1,500 pounds of hemp per acre, we can produce two crops per year, and the price of hemp is at an average of $50 dollars per pound, this initiative has the potential to produce significant revenues for the Company. This will also provide a base of operations for several other equally exciting initiatives. We have been working on this property acquisition for a very long time and are excited about the possibilities it opens up for the Company.”
The property recently acquired..
 NetworkNewsWire Stories : https://www.networknewswire.com/?s=gryn
Green Hygienics Holdings Inc.
CUSIP Number: 393057203
Listed: OTCPINK
Trading Symbol: GRYN
Shares Outstanding: 34,707,835
Transfer Agent: VStock Transfer
Financial Reporting/Disclosure 
Reporting Status: U.S. Fully Reporting SEC Filer
Audited Financials: Latest Report – April 30, 2018
Fiscal Year End: July 31, 2018
Incorporated In: NV, USA
Service Providers 
Accounting/Auditing Firm:
Lonny Wong

***************************************************************************

 

 

Ron

https://stockpicksbyrigatoni.com/disclaimer/

 

Have a great day!

 

 

JOIN NOW